Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.

Abstract

We assessed the impact of a reduced-dose (10 mg x 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.

• Authors: Pier Luigi Zinzani, Lapo Alinari, Monica Tani, Mariapaola Fina, Stefano Pileri, Michele Baccarani
• Journal: Haematologica (Haematologica) Vol. 90 Issue 5 Pg. 702-3 (May 2005) ISSN: 1592-8721 [Electronic] Italy
• PMID: 15921394 (Publication Type: Clinical Trial, Phase II, Letter)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm
• Antineoplastic Agents
• Alemtuzumab

Topics

• Aged
• Alemtuzumab
• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm (administration & dosage, therapeutic use)
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Combined Modality Therapy
• Cytomegalovirus (physiology)
• Cytomegalovirus Infections (etiology)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Humans
• Lymphoma, T-Cell, Cutaneous (drug therapy)
• Lymphoma, T-Cell, Peripheral (drug therapy)
• Male
• Middle Aged
• PUVA Therapy
• Pilot Projects
• Remission Induction
• Virus Activation